BILASON TABLETS 20MG [SIN17610P]
Active ingredients: BILASTINE
Product Info
BILASON TABLETS 20MG
[SIN17610P]
Product information
Active Ingredient and Strength | BILASTINE - 20 MG |
Dosage Form | TABLET |
Manufacturer and Country | UNISON PHARMACEUTICALS PVT. LTD. - INDIA |
Registration Number | SIN17610P |
Licence Holder | ALMA-A PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | RO6AX29 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
Indication
Symptomatic treatment of allergic rhino-conjunctivitis and urticaria in adults and adolescents (12 years of age and over).
Dosing
Posology and method of administration
Route of administration:
Oral Use
Adults and adolescents (12 years of age and over)
20 mg (1 tablet) once daily for the relief of symptoms of allergic rhinoconjunctivitis (SAR and PAR) and urticaria.
The tablet should be taken by oral route one hour before or two hours after intake of food or fruit juice. It is recommended to take the daily dose in one single intake. (See section Interaction with other medicinal products and other forms of interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Elderly
No dosage adjustments are required in elderly patients (see section Pharmacodynamics and Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). There is little experience in patients above the age of 65.
Children under 12 years
The safety and efficacy of bilastine tablet 20 mg in children under 12 years of age have not yet been established.
Renal impairment
No dosage adjustment is required in adult patients with renal impairment. (See section Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
There is no clinical experience in patients with hepatic impairment. However, since bilastine is not metabolized and is eliminated as unchanged in urine and feces, hepatic impairment is not expected to increase systemic exposure above the safety margin in adult patients. Therefore, no dosage adjustment is required in adult patients with hepatic impairment (see section Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Duration of treatment:
For allergic rhinitis the treatment should be limited to the period of exposure to allergens. For seasonal allergic rhinitis treatment could be discontinued after the symptoms have resolved and reinitiated upon their reappearance. In perennial allergic rhinitis continued treatment may be proposed to the patients during the allergen exposure periods. For urticaria the duration of treatment depends on the type, duration and course of the complaints.
Contraindications
Contraindication
Hypersensitivity to the active substance bilastine or to any of the excipients of this medicine. (section List of excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
